Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research

David Buchbinder; Ruta Brazauskas; Khalid Bo-Subait; Karen Ballen; Susan Parsons; Tami John; Theresa Hahn; Akshay Sharma; Amir Steinberg; Anita D'Souza; Anita J. Kumar; Ayami Yoshimi; Baldeep Wirk; Bronwen Shaw; César Freytes; Charles LeMaistre; Christopher Bredeson; Christopher Dandoy; David Almaguer; David I. Marks; David Szwajcer; Gregory Hale; Harry Schouten; Hasan Hashem; Hélène Schoemans; Hemant S. Murthy; Hillard M. Lazarus; Jan Cerny; Jason Tay; Jean A. Yared; Kehinde Adekola; Kirk R. Schultz; Leslie Lehmann; Linda Burns; Mahmoud Aljurf; Miguel Angel Diaz; Navneet Majhail; Nosha Farhadfar; Rammurti Kamble; Richard Olsson; Raquel Schears; Sachiko Seo; Sara Beattie; Saurabh Chhabra; Bipin N. Savani; Sherif Badawy; Siddhartha Ganguly; Stefan Ciurea; Susana Marino; Usama Gergis; Yachiyo Kuwatsuka; Yoshihiro Inamoto; Nandita Khera; Shahrukh Hashmi; William Wood; Wael Saber

doi:10.1016/j.bbmt.2019.11.003

Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research

David Buchbinder, Ruta Brazauskas, Khalid Bo-Subait, Karen Ballen, Susan Parsons, Tami John, Theresa Hahn, Akshay Sharma, Amir Steinberg, Anita D'Souza, Anita J. Kumar, Ayami Yoshimi, Baldeep Wirk, Bronwen Shaw, César Freytes, Charles LeMaistre, Christopher Bredeson, Christopher Dandoy, David Almaguer, David I. MarksDavid Szwajcer, Gregory Hale, Harry Schouten, Hasan Hashem, Hélène Schoemans, Hemant S. Murthy, Hillard M. Lazarus, Jan Cerny, Jason Tay, Jean A. Yared, Kehinde Adekola, Kirk R. Schultz, Leslie Lehmann, Linda Burns, Mahmoud Aljurf, Miguel Angel Diaz, Navneet Majhail, Nosha Farhadfar, Rammurti Kamble, Richard Olsson, Raquel Schears, Sachiko Seo, Sara Beattie, Saurabh Chhabra, Bipin N. Savani, Sherif Badawy, Siddhartha Ganguly, Stefan Ciurea, Susana Marino, Usama Gergis, Yachiyo Kuwatsuka, Yoshihiro Inamoto, Nandita Khera, Shahrukh Hashmi, William Wood, Wael Saber

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.

Original language	English (US)
Pages (from-to)	553-561
Number of pages	9
Journal	Biology of Blood and Marrow Transplantation
Volume	26
Issue number	3
DOIs	https://doi.org/10.1016/j.bbmt.2019.11.003
State	Published - Mar 2020

Keywords

Bone marrow transplantation
Lost to follow-up
Stem cell transplantation
Survivor

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2019.11.003

Cite this

Buchbinder, D., Brazauskas, R., Bo-Subait, K., Ballen, K., Parsons, S., John, T., Hahn, T., Sharma, A., Steinberg, A., D'Souza, A., Kumar, A. J., Yoshimi, A., Wirk, B., Shaw, B., Freytes, C., LeMaistre, C., Bredeson, C., Dandoy, C., Almaguer, D., ... Saber, W. (2020). Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 26(3), 553-561. https://doi.org/10.1016/j.bbmt.2019.11.003

Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors : A Report from the Center for International Blood and Marrow Transplant Research. / Buchbinder, David; Brazauskas, Ruta; Bo-Subait, Khalid et al.

In: Biology of Blood and Marrow Transplantation, Vol. 26, No. 3, 03.2020, p. 553-561.

Research output: Contribution to journal › Article › peer-review

Buchbinder, D, Brazauskas, R, Bo-Subait, K, Ballen, K, Parsons, S, John, T, Hahn, T, Sharma, A, Steinberg, A, D'Souza, A, Kumar, AJ, Yoshimi, A, Wirk, B, Shaw, B, Freytes, C, LeMaistre, C, Bredeson, C, Dandoy, C, Almaguer, D, Marks, DI, Szwajcer, D, Hale, G, Schouten, H, Hashem, H, Schoemans, H, Murthy, HS, Lazarus, HM, Cerny, J, Tay, J, Yared, JA, Adekola, K, Schultz, KR, Lehmann, L, Burns, L, Aljurf, M, Diaz, MA, Majhail, N, Farhadfar, N, Kamble, R, Olsson, R, Schears, R, Seo, S, Beattie, S, Chhabra, S, Savani, BN, Badawy, S, Ganguly, S, Ciurea, S, Marino, S, Gergis, U, Kuwatsuka, Y, Inamoto, Y, Khera, N, Hashmi, S, Wood, W & Saber, W 2020, 'Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research', Biology of Blood and Marrow Transplantation, vol. 26, no. 3, pp. 553-561. https://doi.org/10.1016/j.bbmt.2019.11.003

@article{30a8ad0f444f47109592b0b1cdbf08a5,

title = "Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research",

abstract = "Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.",

keywords = "Bone marrow transplantation, Lost to follow-up, Stem cell transplantation, Survivor",

author = "David Buchbinder and Ruta Brazauskas and Khalid Bo-Subait and Karen Ballen and Susan Parsons and Tami John and Theresa Hahn and Akshay Sharma and Amir Steinberg and Anita D'Souza and Kumar, {Anita J.} and Ayami Yoshimi and Baldeep Wirk and Bronwen Shaw and C{\'e}sar Freytes and Charles LeMaistre and Christopher Bredeson and Christopher Dandoy and David Almaguer and Marks, {David I.} and David Szwajcer and Gregory Hale and Harry Schouten and Hasan Hashem and H{\'e}l{\`e}ne Schoemans and Murthy, {Hemant S.} and Lazarus, {Hillard M.} and Jan Cerny and Jason Tay and Yared, {Jean A.} and Kehinde Adekola and Schultz, {Kirk R.} and Leslie Lehmann and Linda Burns and Mahmoud Aljurf and Diaz, {Miguel Angel} and Navneet Majhail and Nosha Farhadfar and Rammurti Kamble and Richard Olsson and Raquel Schears and Sachiko Seo and Sara Beattie and Saurabh Chhabra and Savani, {Bipin N.} and Sherif Badawy and Siddhartha Ganguly and Stefan Ciurea and Susana Marino and Usama Gergis and Yachiyo Kuwatsuka and Yoshihiro Inamoto and Nandita Khera and Shahrukh Hashmi and William Wood and Wael Saber",

note = "Funding Information: Financial disclosure: Dr. Ganguly receives support from Seattle Genetics, Kite Phrama, Janssen Pharmaceuticals, and Daiichi Sankyo. Conflict of interest statement: S.G. receives support from Seattle Genetics, Kite Pharma, Janssen Pharmaceuticals, and Daiichi Sankyo. Financial disclosure: See Acknowledgments on page 560. Funding Information: Financial disclosure: Dr. Ganguly receives support from Seattle Genetics, Kite Phrama, Janssen Pharmaceuticals, and Daiichi Sankyo. Conflict of interest statement: S.G. receives support from Seattle Genetics, Kite Pharma, Janssen Pharmaceuticals, and Daiichi Sankyo. Publisher Copyright: {\textcopyright} 2019 American Society for Transplantation and Cellular Therapy",

year = "2020",

month = mar,

doi = "10.1016/j.bbmt.2019.11.003",

language = "English (US)",

volume = "26",

pages = "553--561",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors

T2 - A Report from the Center for International Blood and Marrow Transplant Research

AU - Buchbinder, David

AU - Brazauskas, Ruta

AU - Bo-Subait, Khalid

AU - Ballen, Karen

AU - Parsons, Susan

AU - John, Tami

AU - Hahn, Theresa

AU - Sharma, Akshay

AU - Steinberg, Amir

AU - D'Souza, Anita

AU - Kumar, Anita J.

AU - Yoshimi, Ayami

AU - Wirk, Baldeep

AU - Shaw, Bronwen

AU - Freytes, César

AU - LeMaistre, Charles

AU - Bredeson, Christopher

AU - Dandoy, Christopher

AU - Almaguer, David

AU - Marks, David I.

AU - Szwajcer, David

AU - Hale, Gregory

AU - Schouten, Harry

AU - Hashem, Hasan

AU - Schoemans, Hélène

AU - Murthy, Hemant S.

AU - Lazarus, Hillard M.

AU - Cerny, Jan

AU - Tay, Jason

AU - Yared, Jean A.

AU - Adekola, Kehinde

AU - Schultz, Kirk R.

AU - Lehmann, Leslie

AU - Burns, Linda

AU - Aljurf, Mahmoud

AU - Diaz, Miguel Angel

AU - Majhail, Navneet

AU - Farhadfar, Nosha

AU - Kamble, Rammurti

AU - Olsson, Richard

AU - Schears, Raquel

AU - Seo, Sachiko

AU - Beattie, Sara

AU - Chhabra, Saurabh

AU - Savani, Bipin N.

AU - Badawy, Sherif

AU - Ganguly, Siddhartha

AU - Ciurea, Stefan

AU - Marino, Susana

AU - Gergis, Usama

AU - Kuwatsuka, Yachiyo

AU - Inamoto, Yoshihiro

AU - Khera, Nandita

AU - Hashmi, Shahrukh

AU - Wood, William

AU - Saber, Wael

N1 - Funding Information: Financial disclosure: Dr. Ganguly receives support from Seattle Genetics, Kite Phrama, Janssen Pharmaceuticals, and Daiichi Sankyo. Conflict of interest statement: S.G. receives support from Seattle Genetics, Kite Pharma, Janssen Pharmaceuticals, and Daiichi Sankyo. Financial disclosure: See Acknowledgments on page 560. Funding Information: Financial disclosure: Dr. Ganguly receives support from Seattle Genetics, Kite Phrama, Janssen Pharmaceuticals, and Daiichi Sankyo. Conflict of interest statement: S.G. receives support from Seattle Genetics, Kite Pharma, Janssen Pharmaceuticals, and Daiichi Sankyo. Publisher Copyright: © 2019 American Society for Transplantation and Cellular Therapy

PY - 2020/3

Y1 - 2020/3

N2 - Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.

AB - Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.

KW - Bone marrow transplantation

KW - Lost to follow-up

KW - Stem cell transplantation

KW - Survivor

UR - http://www.scopus.com/inward/record.url?scp=85076525725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076525725&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.11.003

DO - 10.1016/j.bbmt.2019.11.003

M3 - Article

C2 - 31726205

AN - SCOPUS:85076525725

VL - 26

SP - 553

EP - 561

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -

Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this